Patient characteristics associated with the need for high doses of tenapanor hydrochloride in dialysis patients with hyperphosphatemia: A pooled analysis of three clinical trials
Nobuo Nagano, Shin Tokunaga, Shinji Asada, Masafumi Fukagawa, Tadao Akizawa · 2026
Read Patient characteristics associated with the need for high doses of tenapanor hydrochloride in dialysis patients with hyperphosphatemia: A pooled analysis of three clinical trials by Nobuo Nagano, Shin Tokunaga, Shinji Asada, Masafumi Fukagawa, Tadao Akizawa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0356873.txt.
Description
Nobuo Nagano and colleagues pool three Japanese clinical trials of tenapanor, a newer drug for the phosphate build-up that plagues dialysis patients. Failing kidneys cannot clear phosphate, which drives bone and heart harm; older binder pills work but pile up daily doses that patients skip. Tenapanor instead blocks phosphate absorption in the gut, and its dose is raised step by step until blood levels respond, though stomach side effects make some patients resist higher doses.
The pooled analysis asks which patient traits mark those who end up needing the high end of the dose range. Knowing the profile in advance could help doctors counsel patients and set expectations before titration begins. Nagano and colleagues draw on the three registered trials' combined records for this prescribing question.
Catalog record
| CREATOR | Nobuo Nagano, Shin Tokunaga, Shinji Asada, Masafumi Fukagawa, Tadao Akizawa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30159 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |